Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.

The Advent and ideation

Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.

Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.

“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.

No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.

FDA's Role in the Push

The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.

Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.

What Could Be The Challenges?

Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.

Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.

Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.

Could Low-Nicotine Cigarettes Be The Solution?

Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.

Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.

Artificial intelligence has steadily been becoming a bigger part of the healthcare sector. One of the biggest examples is ChatGPT.

Open AI recently begun rolling out Health in ChatGPT to eligible users in the United States, allowing people to securely connect medical records, Apple Health data, and other supported health sources directly to ChatGPT.

The feature aims to help users in understanding their lab reports better, document their medical history, prepare for doctor visits, and gauge complex medical information.

While it promises convenience and personalised health insights, it has also sparked concerns about privacy, data security, and how much trust people should place in AI for healthcare decisions.

What Is ChatGPT Health?

It is currently available on the web and iOS for eligible Free, Go, Plus, and Pro users in the US, with the rollout happening gradually. 

Once connected, users can ask questions such as:

• What has changed between my latest and previous blood tests?

• Can you explain my cholesterol report in simple language?

• How are my sleep and exercise affecting my overall health?

• What questions should I ask my doctor during my next appointment?

Instead of uploading reports every time, ChatGPT can use connected health information, with the user’s permission, to provide more personalized explanations. 

Also read: AIIMS Doctor Issues Warning After Patient Follows ChatGPT Advice, Suffers Internal Bleeding

OpenAI Emphasises Privacy

According to the company, “Health is designed to support; not replace, medical care and is not intended for final diagnosis or treatment. For urgent symptoms or emergencies, seek immediate professional help.” 

The company also states, “Conversations in Health are not used to train our foundation models.” 

Users can disconnect connected accounts whenever they choose. OpenAI says synced data from disconnected sources is deleted from its systems within 30 days, although information already included in conversation history remains unless users delete those chats. 

Pros And Cons Of ChatGPT Health

How Can It Help?

Makes Medical Reports Easier To Comprehend

Medical records often contain technical terminology that patients struggle to interpret.

AI can translate complicated reports into simpler language that laymen can understand.

Saves Time Before Doctor Visits

Patients can review previous reports, organise symptoms, and prepare questions before appointments, making doctor visits more productive.

Maintains Medical History

People often have information spread across hospital portals, physical files, wearable devices, and fitness apps.

ChatGPT can combine these sources to identify patterns over time, like changes in sleep, physical activity, or important bio markers. 

Supports Better Health Tracking

Rather than searching through multiple reports manually, users can quickly compare test results or check long-term changes with simple prompts.

Also read: Man Falls Ill After Seeking ChatGPT Advice on Cutting Salt

Potential Downsides

Despite the advantages, experts caution against relying too heavily on AI for healthcare.

Privacy Concerns

Although OpenAI has introduced additional security measures, users are still sharing extremely sensitive personal health information with an AI platform.

Some AI privacy experts argue that any cloud-based storage of medical information is risky.

AI Can Still Make Mistakes

ChatGPT can explain information but may misunderstand context, overlook rare conditions, or generate inaccurate answers.

OpenAI clearly states that the feature must not replace professional medical advice, diagnosis, or treatment. 

Risk of Delaying Medical Care

The launch comes amid renewed scrutiny over AI-generated medical advice.

A recently filed lawsuit alleges that a user delayed seeking emergency treatment after relying on ChatGPT’s health guidance.

While the allegations are still part of ongoing legal proceedings, the case has intensified discussions about the limitations of AI in healthcare. 

Should You Give AI Access To Your Medical Records?

If your goal is to better understand your lab reports, organise medical information, or prepare for doctor consultations, ChatGPT Health could become a useful health assistant.

However, if you are expecting AI to diagnose illnesses, decide treatments, or replace healthcare professionals, experts say that would be a mistake.

Healthcare decisions often depend on physical examinations, medical history, imaging, and clinical judgment, areas where AI cannot replace qualified doctors.

The human brain may begin undergoing important immune changes much earlier than previously thought. A recent study found that these changes could help explain why the risk of dementia increases with age.

Researchers found that the hippocampus, the brain region responsible for learning and memory, experiences a major shift in its immune cells during the 40s and 50s.

The findings suggest that this change could lead to chronic inflammation associated with Alzheimer's disease and other forms of dementia in the future .

What Did The Study Find?

The study, conducted by scientists from the University of California San Diego, the New York Genome Center, and the University of California Irvine, analysed postmortem hippocampal tissue from 40 neurologically healthy adults aged between 20 and 95 years.

Researchers examined more than 1.2 million brain cells, discovering that around midlife, the brain's immune environment changes dramatically.

One of the biggest findings involved microglia, the brain's resident immune cells. While these cells normally protect the brain by clearing debris, fighting infections, and supporting neurons, researchers observed that they gradually shift into a more inflammatory state during middle age.

This altered immune environment resembles patterns commonly seen in neurodegenerative diseases like dementia.

Also read: World Brain Day: Climate Change Is Not Just Harming The Planet, It Could Also Be Affecting Your Brain

Link Between Ageing & Dementia

Scientists have long known that aging is the strongest risk factor for dementia. However, exactly how normal aging causes diseases like Alzheimer's has remained vague.

The new findings suggest that the process may begin decades before symptoms like memory loss appear.

Instead of viewing aging as a slow, continuous process, the study indicates that the brain may pass through a distinct biological transition during midlife.

Once this immune environment changes, it may make the brain more vulnerable to inflammation and cognitive decline.

Richard J. Hodes, MD, Director of the National Institute on Aging (NIA), said, "Aging is the single largest risk factor for dementia, but our understanding of how it drives disease is still incomplete. This previously hidden microglial shift, now uncovered by innovations in technology and thinking, may be an important clue to help us complete the puzzle."

The researchers also believe these immune changes may not simply be a consequence of aging but could actively influence how the brain ages.

Also read: Can One Partner's Dementia Raise the Other's Risk? New Study Suggests An Interesting Link

Could This Contribute In Dementia Treatments & Management?

Although the findings do not mean that everyone in their 40s or 50s will develop dementia, they provide researchers with a potential window for clinical intervention.

If scientists can identify or modify these immune changes before significant brain damage occurs, future therapies may be able to delay or even prevent neurodegenerative diseases.

Experts continue to recommend:

• Keeping blood pressure, blood sugar, and cholesterol under control.
• Exercising regularly.
• Getting adequate sleep.
• Eating a balanced, brain-healthy diet.
• Staying mentally and socially active.
• Managing hearing loss and avoiding smoking.

These lifestyle measures are already known to reduce several risk factors associated with dementia, and the new findings suggest they may be particularly important during the brain's midlife transition.

A six-year-old girl in China died after receiving an experimental gene-editing treatment for a rare neurodevelopmental disorder. The incident sparked scrutiny on ethics and safety of cutting-edge gene therapies, particularly when they involve children and individualized treatments.

The case, uncovered through a joint investigation by Science and Retraction Watch, sparked international concern as the child's death was never disclosed publicly, despite related preclinical research later being published in Nature.

What Happened?

According to the investigation, the six-year-old girl, identified by the pseudonym "Mei," had Snijders Blok-Campeau syndrome, a rare genetic condition. It caused symptoms like mild intellectual disability and developmental delays.

Her parents reportedly paid more than $800,000 to support development of a personalized ("n=1") gene-editing therapy designed specifically for their daughter's mutation.

In March 2025, she received a spinal infusion containing trillions of adeno-associated viruses (AAVs) carrying a CRISPR-based gene editor intended to correct the faulty gene in brain cells. Within days, she developed a severe immune reaction and died approximately one week after treatment.

An internal hospital review concluded that the most likely cause of death was an overwhelming immune response triggered by the viral delivery system rather than the gene-editing mechanism itself.

The controversy extends well beyond the patient's death. According to Science investigation:

• The child's death was not publicly disclosed.
• The child's treatment was omitted from a later Nature publication describing related preclinical work.
• Animal studies had reportedly shown warning signs, including severe liver and kidney toxicity at high doses.
• The girl's parents may not have been fully informed about the potential side effects of the therapy.

Following the investigation, local Chinese health authorities reportedly fined the hospital involved for faulty execution of the clinical research. Several experts have called for an independent review of the published research and greater transparency around experimental human gene-editing trials.

Also read: Ebola Outbreak in DR Congo Nears 3,000 Cases, 1,300 Deaths as UN Warns Virus Is 'Spreading Like Wildfire'

Bioethicists and gene therapy researchers say the case underscores the need for complete transparency whenever experimental therapies are tested on humans.

Hank Greely, director of the Center for Law and the Biosciences at Stanford University, told Science that the trial "shouldn't have gone to trial".

Pediatrician Marcelo Bellusci, who participates in gene therapy trials, told El País, "In this type of trial there can be serious side effects, but families are always informed about them. This team skipped the current rules."

About Gene-Editing Therapies

Gene-editing technologies such as CRISPR offer the possibility of correcting genetic mutations caused by diseases instead of simply treating symptoms. Several CRISPR-based therapies have shown remarkable success in inherited blood disorders, including sickle cell disease.

However, experts stress that therapies targeting the brain remain considerably more complex because they often require large viral doses and carry greater risks of immune complications.

As more individualized gene-editing therapies move toward human testing, experts argue that every serious adverse event must be reported promptly to regulators, journals, clinicians, and patients to ensure future treatments become both safer and more trustworthy.